Improve Research Reproducibility A Bio-protocol resource
- Home
- Protocols
-
Ask a
question
Favorite
Inclusion: The use of PI3Kγ selective inhibitors (can be delta/gamma isoform specific) as mono- or combinational therapy for cancer. All timings, dosages, frequencies, and administration routes.
Exclusion: Treatment involving Pan PI3K inhibitors (not described as gamma selective) or genetic depletion of PI3Kγ (e.g. knockout mice).
Copyright and License information: The Author(s) ©2024
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Post a Question0 Q&A
